Sugi Predict

Sugi Predict / Compounds / SCHEMBL23324448

SCHEMBL23324448

SCHEMBL23324448

CC(C)[C@@H](C(=O)OC(C)(C)C)N(C)C(=O)C1(F)CCN(C(=O)OC(C)(C)C)CC1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ USP30 Q70CQ3 1/20 0.39
▸ TSHR P16473 2/20 0.38
▸ ALOX15 P16050 1/20 0.38
▸ USP2 O75604 1/20 0.38
▸ SMN1; SMN2 Q16637 1/20 0.38
▸ ATM Q13315 2/20 0.34
▸ HTT P42858 2/20 0.33
▸ HPGD P15428 1/20 0.33
▸ EPHX2 P34913 1/20 0.33
▸ MEN1 O00255 2/20 0.33
▸ KMT2A Q03164 2/20 0.33
▸ NPC1 O15118 1/20 0.33
▸ ALDH1A1 P00352 1/20 0.33
▸ MAPT P10636 1/20 0.33
▸ MAPK1 P28482 1/20 0.33
▸ RAB9A P51151 1/20 0.33
▸ L3MBTL1 Q9Y468 1/20 0.33
▸ DDB1 Q16531 1/20 0.32
▸ CRBN Q96SW2 1/20 0.32
▸ RECQL P46063 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28822019 1.00 USP30 (0.39) USP30TSHRALOX15USP2SMN1; SMN2
SCHEMBL23295392 0.90 USP30 (0.35) USP30TSHRALOX15
SCHEMBL23295390 0.90 USP30 (0.35) USP30TSHRALOX15
SCHEMBL22156359 0.88 USP30 (0.36) USP30TSHRALOX15USP2SMN1; SMN2
SCHEMBL22152249 0.88 USP30 (0.36) USP30TSHRALOX15USP2SMN1; SMN2
SCHEMBL23295326 0.82 NRAS (0.33) USP30
SCHEMBL23295328 0.82 NRAS (0.33) USP30
SCHEMBL23295647 0.81 ABCB1 (0.32) —
SCHEMBL23295645 0.81 ABCB1 (0.32) —
SCHEMBL22128317 0.80 USP30 (0.32) USP30

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260078133-A1 RAS INHIBITORS Revolution Medicines, Inc. 2026-03-19 — — US disclosed
EP-4696316-A2 RAS INHIBITORS Revolution Medicines, Inc. (US) 2026-02-18 — — EP disclosed
US-20260042740-A1 RAS INHIBITORS REVOLUTION MEDICINES INC (US) 2026-02-12 — — US disclosed
EP-4054719-B1 RAS INHIBITORS REVOLUTION MEDICINES INC (US) 2026-02-11 — — EP disclosed
US-12384750-B2 Ras inhibitors Revolution Medicines, Inc. (US) 2025-08-12 — — US disclosed
US-20250195521-A1 USE OF SOS1 INHIBITORS TO TREAT MALIGNANCIES WITH SHP2 MUTATIONS Revolution Medicines, Inc. 2025-06-19 — — US disclosed
US-11952352-B2 Ras inhibitors Revolution Medicines, Inc. (US) 2024-04-09 — — US disclosed
US-20230233569-A1 METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT 2023-07-27 — — US disclosed
US-20230234929-A1 RAS INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT 2023-07-27 — — US disclosed
US-20230234929-A1 RAS INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT 2023-07-27 — — US disclosed
CN-116209438-A Treatment of malignant diseases with SHP2 mutations using SOS1 inhibitors 锐新医药公司 2023-06-02 — — CN disclosed
EP-4168002-A1 METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS Revolution Medicines, Inc. (US) 2023-04-26 — — EP disclosed
CN-115916194-A Methods for delaying, preventing and treating acquired resistance to RAS inhibitors 锐新医药公司 2023-04-04 — — CN disclosed
CN-115894606-A RAS inhibitors 锐新医药公司 2023-04-04 — — CN disclosed
US-11566007-B2 Ras inhibitors Revolution Medicines, Inc. (US) 2023-01-31 — — US disclosed
US-11566007-B2 Ras inhibitors Revolution Medicines, Inc. (US) 2023-01-31 — — US disclosed
EP-4054719-A1 RAS INHIBITORS Revolution Medicines, Inc. (US) 2022-09-14 — — EP disclosed
CN-114786777-A RAS inhibitors 锐新医药公司 2022-07-22 — — CN disclosed
WO-2022060583-A1 USE OF SOS1 INHIBITORS TO TREAT MALIGNANCIES WITH SHP2 MUTATIONS Revolution Medicines, Inc. (US) 2022-03-24 — — WO disclosed
US-20210130303-A1 RAS INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT 2021-05-06 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260078133-A1 RAS INHIBITORS KRAS, NRAS, HRAS USP30 1583/4885TSHR 2426/4885ALOX15 4659/4885
US-20260042740-A1 RAS INHIBITORS KRAS, NRAS, HRAS USP30 1448/4885TSHR 1880/4885ALOX15 4609/4885
US-20250195521-A1 USE OF SOS1 INHIBITORS TO TREAT MALIGNANCIES WITH SHP2 MUTATIONS SOS1, PPM1D, PTPN1 USP30 785/4885TSHR 2038/4885ALOX15 4271/4885
US-11566007-B2 Ras inhibitors KRAS, NRAS, HRAS USP30 1265/4885TSHR 3332/4885ALOX15 4589/4885
US-20230234929-A1 RAS INHIBITORS KRAS, NRAS, HRAS USP30 1265/4885TSHR 3332/4885ALOX15 4589/4885
US-20230233569-A1 METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS KRAS, HRAS, MTOR USP30 1221/4885TSHR 4120/4885ALOX15 3782/4885
US-20210130303-A1 RAS INHIBITORS KRAS, NRAS, HRAS USP30 1265/4885TSHR 3332/4885ALOX15 4589/4885
US-12384750-B2 Ras inhibitors KRAS, NRAS, HRAS USP30 1265/4885TSHR 3332/4885ALOX15 4589/4885
US-11952352-B2 Ras inhibitors KRAS, NRAS, HRAS USP30 1265/4885TSHR 3332/4885ALOX15 4589/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.